Eurobio Scientific Société anonyme (ALERS.PA) Stock

About Eurobio Scientific Société anonyme

Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. The company's portfolio features the Tetanus Quick Stick, an essential emergency diagnostic for rapidly determining a patient's tetanus vaccination status. It also distributes cell culture media, molecular biology reagents, and proprietary antibody solutions. Proprietary developments from Eurobio Scientific encompass the BJI InoPlex, a multiplex serological test for diagnosing prosthetic joint infections, and the EBX-044 PCR test, utilized for identifying SARS-CoV-2 variants. Its licensed offerings include AlloMap, a gene-expression profiling blood test designed for the ongoing surveillance of heart transplant recipients. The firm, initially named Diaxonhit, changed its corporate identity to Eurobio Scientific S.A. in June 2018. Founded in 1997, the company is headquartered in Les Ulis, France.

Eurobio Scientific Société anonyme is led by CEO Denis Fortier, employs 343 people, headquartered in Les Ulis, FR, publicly traded since 2005.

over the past 52 weeks the stock has ranged between $19.30 and $25.70, and currently trades 18.7% below its 52-week high.

Official website: www.eurobio-scientific.com